Do no harm: managing nausea and vomiting in GLP-1 based obesity therapies - PubMed
7 hours ago
- #government
- #diabetes
- #healthcare
- Official U.S. government websites use .gov or .mil domains.
- Ensure the site is secure (https://) before sharing sensitive information.
- CR received personal fees from multiple pharmaceutical companies outside the submitted work.
- Other authors declared no potential conflicts of interest.
- References discuss GLP-1-based medications for type 2 diabetes and obesity, patient discontinuation reasons, side effects management, safety, and oral Semaglutide studies.